Tuberculosis Clinical Immunology

[1]  W. Bishai,et al.  Risk of tuberculosis reactivation with tofacitinib (CP-690550). , 2012, The Journal of infectious diseases.

[2]  H. Yamanaka,et al.  Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients , 2011, Annals of the rheumatic diseases.

[3]  S. Singhal,et al.  Correlation of sputum smear status with CD4 count in cases of pulmonary tuberculosis and HIV co-infected patients--a hospital based study in a rural area of Central India. , 2011, The Indian journal of tuberculosis.

[4]  M. Christiansen,et al.  Novel STAT1 Alleles in a Patient with Impaired Resistance to Mycobacteria , 2011, Journal of Clinical Immunology.

[5]  F. Tubach,et al.  Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry , 2010, Annals of the rheumatic diseases.

[6]  Smita Y. Patel,et al.  Revisiting Human IL-12R&bgr;1 Deficiency: A Survey of 141 Patients From 30 Countries , 2010, Medicine.

[7]  A. Crampin,et al.  Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi , 2010, AIDS.

[8]  K. Higuchi,et al.  Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis. , 2008, Tuberculosis.

[9]  Pan‐Chyr Yang,et al.  Prediction of the tuberculosis reinfection proportion from the local incidence. , 2007, The Journal of infectious diseases.

[10]  J. Eschard,et al.  Tuberculose lors d'un traitement par agents inhibiteurs du TNF alpha , 2006 .

[11]  M. Lederman,et al.  Biology of CCR5 and its role in HIV infection and treatment. , 2006, JAMA.

[12]  Mahboob Rahman,et al.  Glucocorticoid use, other associated factors, and the risk of tuberculosis. , 2006, Arthritis and rheumatism.

[13]  R. Wallis.  Reconsidering adjuvant immunotherapy for tuberculosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Kuskowski,et al.  Host-pathogen relationships among Escherichia coli isolates recovered from men with febrile urinary tract infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Ellner,et al.  Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. , 2005, The Journal of infectious diseases.

[16]  M. Broder,et al.  Granulomatous infections due to tumor necrosis factor blockade: correction. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  P. Haslett,et al.  Adjunctive Thalidomide Therapy for Childhood Tuberculous Meningitis: Results of a Randomized Study , 2004, Journal of child neurology.

[18]  John L. Johnson,et al.  A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis , 2004, AIDS.

[19]  D. Schroeder,et al.  Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. , 2003, Chest.

[20]  P. Sonnenberg,et al.  HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers , 2001, The Lancet.

[21]  M. Levin,et al.  Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria. , 2000, The Journal of infectious diseases.

[22]  P. Rudge,et al.  PARADOXICAL EXPANSION OF INTRACRANIAL TUBERCULOMAS DURING CHEMOTHERAPY , 1984, The Lancet.

[23]  R. Wallis,et al.  Sustainable tuberculosis drug development. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.